Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:DIVI NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDIVIFranklin International Core Dividend Tilt Index ETF$42.94+1.1%$41.00$34.03▼$43.21$2.49B0.69233,001 shs135,830 shsSLSSELLAS Life Sciences Group$5.01+1.6%$4.93$1.36▼$6.14$924.51M2.244.28 million shs3.40 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDIVIFranklin International Core Dividend Tilt Index ETF+1.13%+1.92%+2.95%+2.24%+25.70%SLSSELLAS Life Sciences Group+1.62%+1.62%-0.79%+34.32%+192.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDIVIFranklin International Core Dividend Tilt Index ETF$42.94+1.1%$41.00$34.03▼$43.21$2.49B0.69233,001 shs135,830 shsSLSSELLAS Life Sciences Group$5.01+1.6%$4.93$1.36▼$6.14$924.51M2.244.28 million shs3.40 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDIVIFranklin International Core Dividend Tilt Index ETF+1.13%+1.92%+2.95%+2.24%+25.70%SLSSELLAS Life Sciences Group+1.62%+1.62%-0.79%+34.32%+192.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDIVIFranklin International Core Dividend Tilt Index ETF 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 2.00Hold$10.0099.60% UpsideCurrent Analyst Ratings BreakdownLatest DIVI, SLS, TRG, and BGFD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026SLSSELLAS Life Sciences Group Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.00(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDIVIFranklin International Core Dividend Tilt Index ETFN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDIVIFranklin International Core Dividend Tilt Index ETFN/AN/A14.82N/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$26.86M-$0.25N/AN/AN/AN/A-63.06%-54.50%5/12/2026 (Estimated)Latest DIVI, SLS, TRG, and BGFD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06N/AN/AN/AN/AN/A3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDIVIFranklin International Core Dividend Tilt Index ETF$1.513.52%N/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDIVIFranklin International Core Dividend Tilt Index ETFN/AN/AN/ASLSSELLAS Life Sciences GroupN/A10.7210.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDIVIFranklin International Core Dividend Tilt Index ETFN/ASLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipDIVIFranklin International Core Dividend Tilt Index ETFN/ASLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDIVIFranklin International Core Dividend Tilt Index ETFN/A58.00 millionN/ANot OptionableSLSSELLAS Life Sciences Group10184.53 million181.95 millionNot OptionableDIVI, SLS, TRG, and BGFD HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group (SLS) to Release Earnings on TuesdayMay 10 at 3:53 AM | americanbankingnews.comSLS stock heads for weekly win: Deutsche Bank’s stake boost draws attention ahead of Q1 earningsMay 8 at 7:49 AM | msn.comSELLAS Life Sciences Group (SLS) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comSLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvalsMay 4, 2026 | msn.comSLS stock tests $5 again: Retail targets 'no' vote on 20M share dilution push before AML trial resultsMay 1, 2026 | msn.comSELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20April 28, 2026 | msn.comSLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approvalApril 27, 2026 | msn.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?April 27, 2026 | marketbeat.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 6.79%April 26, 2026 | aaii.comASELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.1% - Here's WhyApril 24, 2026 | marketbeat.comSellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key EventApril 24, 2026 | seekingalpha.comSellas Life Sciences: Behind The Big SurgeApril 22, 2026 | seekingalpha.comSLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data revealApril 21, 2026 | msn.comWall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a BetApril 20, 2026 | zacks.comSLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapyApril 17, 2026 | msn.comSELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia TreatmentApril 14, 2026 | finance.yahoo.comSLS stock rises premarket ahead of cancer summit this month – investors eye phase 3 AML trial milestoneApril 9, 2026 | msn.comSELLAS Life Sciences Group, Inc.April 7, 2026 | edition.cnn.comInvestor Attention Turns to Sellas Life Sciences Ahead of Key Cancer ConferenceApril 3, 2026 | aktiencheck.deASELLAS Life Sciences Group (SLS) price target increased by 26.83% to 8.84March 28, 2026 | msn.comSELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026March 27, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026STMicronelectronics Sends Industrial Chips Into OverdriveBy Thomas Hughes | April 24, 2026The Quiet Infrastructure Play on Small-Bank SurvivalBy Peter Frank | April 21, 20263 Different Fintech Giants: Turnaround, Stability, or Risky Bet?By Peter Frank | April 12, 2026DIVI, SLS, TRG, and BGFD Company DescriptionsFranklin International Core Dividend Tilt Index ETF NYSEARCA:DIVI$42.94 +0.48 (+1.13%) As of 05/8/2026 04:10 PM EasternThe fund invests at least 80% of its assets in the component securities of the index and in depositary receipts representing such securities. The index is based on the Morningstar® Developed Markets ex-North America Target Market Exposure Index and is constructed by applying an optimization process to the Parent Index that aims to deliver a higher dividend yield than the Parent Index, while limiting expected tracking error to the Parent Index.SELLAS Life Sciences Group NASDAQ:SLS$5.01 +0.08 (+1.62%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.00 -0.01 (-0.30%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
